Why Does the True Impact of AI in Drug Discovery Lag?
AI in drug discovery keeps making headlines, but clinical success rates barely move. A new Nature Reviews Perspective explains why, and what pharma should do next.
AlphaGenome Atlas: Mapping Every Possible DNA Variant
Google DeepMind’s AlphaGenome Atlas maps all nine billion possible DNA variants, helping researchers rapidly prioritise disease-linked mutations.
Machine Learning in Drug Discovery: Gains and Data Gaps
Machine learning in drug discovery promises faster drug screening and fewer failures, but weak data limits gains. See what the latest 2026 review means for pharma.
AI Biology: What Biohub’s $1.8bn Push Means for Pharma
In one of the most important developments, AI biology gets a $1.8 billion boost as Biohub, DOE, and the NIH build open and AI-ready data for virtual cell models.
Target Atlas for Smarter Target Prioritisation for Parkinson’s
Target prioritisation gets an evidence upgrade. Find out how Phylo’s Target Atlas and the MJFF Parkinson’s edition rank disease drug targets.
Real-Time Clinical Trials Are a Huge Competitive Advantage
Real-time clinical trials enable continuous data capture and faster decisions, improving how data is used in clinical trials. Here is what pharma leaders need to know.